Albrecht Stöffler

4.4k total citations · 2 hit papers
18 papers, 3.3k citations indexed

About

Albrecht Stöffler is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Neurology. According to data from OpenAlex, Albrecht Stöffler has authored 18 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cellular and Molecular Neuroscience, 6 papers in Psychiatry and Mental health and 4 papers in Neurology. Recurrent topics in Albrecht Stöffler's work include Dementia and Cognitive Impairment Research (6 papers), Neuroscience and Neuropharmacology Research (5 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Albrecht Stöffler is often cited by papers focused on Dementia and Cognitive Impairment Research (6 papers), Neuroscience and Neuropharmacology Research (5 papers) and Parkinson's Disease Mechanisms and Treatments (4 papers). Albrecht Stöffler collaborates with scholars based in Germany, Sweden and United States. Albrecht Stöffler's co-authors include Hans Jörg Möbius, ‌Barry Reisberg, Frederick A. Schmitt, Steven H. Ferris, Rachelle S. Doody, Chris G. Parsons, Wojciech Danysz, Bengt Winblad, Françoise Forette and Anne‐Sophie Rigaud and has published in prestigious journals such as New England Journal of Medicine, Stroke and Neurobiology of Aging.

In The Last Decade

Albrecht Stöffler

18 papers receiving 3.1k citations

Hit Papers

Memantine in Moderate-to-Severe Alzheimer's Disease 2003 2026 2010 2018 2003 2007 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Memantine in Moderate-to-Severe Alzheimer's Disease
    2003 1.5k citations ‌Barry Reisberg, Rachelle S. Doody et al. New England Journal of Medicine profile →
  2. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
    2007 545 citations Chris G. Parsons, Albrecht Stöffler et al. Neuropharmacology profile →

Peers

Albrecht Stöffler
Hans Jörg Möbius Germany
R. H. Perry United Kingdom
Michelle Gee United Kingdom
G K Wilcock United Kingdom
Richard Harvey United Kingdom
F. Müller‐Spahn Switzerland
Lutz Froelich Germany
Peter Bentham United Kingdom
Lynn D. Kramer United States
Taro Kishi Japan
Hans Jörg Möbius Germany
Albrecht Stöffler
Citations per year, relative to Albrecht Stöffler Albrecht Stöffler (= 1×) peers Hans Jörg Möbius

Countries citing papers authored by Albrecht Stöffler

Since Specialization
Citations

This map shows the geographic impact of Albrecht Stöffler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albrecht Stöffler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albrecht Stöffler more than expected).

Fields of papers citing papers by Albrecht Stöffler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albrecht Stöffler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albrecht Stöffler. The network helps show where Albrecht Stöffler may publish in the future.

Co-authorship network of co-authors of Albrecht Stöffler

This figure shows the co-authorship network connecting the top 25 collaborators of Albrecht Stöffler. A scholar is included among the top collaborators of Albrecht Stöffler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albrecht Stöffler. Albrecht Stöffler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Gerlach, Manfred, Walter Maetzler, Karl Broich, et al.. (2011). Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. Journal of Neural Transmission. 119(1). 39–52. 53 indexed citations
3.
Schmidt, Reinhold, et al.. (2008). P2‐074: Effects of memantine on brain volume, glucose metabolism and cognition in Alzheimer's disease patients: A neuroimaging study. Alzheimer s & Dementia. 4(4S_Part_12). 3 indexed citations
4.
Parsons, Chris G., Albrecht Stöffler, & Wojciech Danysz. (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology. 53(6). 699–723. 545 indexed citations breakdown →
5.
Winblad, Bengt, Roy Jones, Yvonne Wirth, Albrecht Stöffler, & Hans Jörg Möbius. (2007). Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials. Dementia and Geriatric Cognitive Disorders. 24(1). 20–27. 190 indexed citations
6.
Reisberg, ‌Barry, Rachelle S. Doody, Albrecht Stöffler, et al.. (2006). A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease. Archives of Neurology. 63(1). 49–49. 134 indexed citations
7.
Wirth, Yvonne, Bengt Winblad, Roy Jones, Albrecht Stöffler, & Hans Jörg Möbius. (2006). P2–406: Efficacy and safety of memantine in moderate to severe Alzheimer's disease – a meta–analysis. Alzheimer s & Dementia. 2(3S_Part_12). 1 indexed citations
8.
Graham, Hamish, Jeffrey M. Jonas, Grace S. Lee, et al.. (2004). P1-343 Memantine is safe for short- and long-term treatment of dementia. Neurobiology of Aging. 25. S195–S195. 2 indexed citations
9.
Möbius, Hans Jörg, Albrecht Stöffler, & Stephen M. Graham. (2004). Memantine hydrochloride: Pharmacological and clinical profile. Drugs of today. 40(8). 685–685. 31 indexed citations
10.
Tariot, Pierre N., Rachelle S. Doody, Elaine R. Peskind, et al.. (2004). P1-021 Memantine treatment for mild to severe Alzheimer's disease: clinical trials summary. Neurobiology of Aging. 25. S99–S100. 4 indexed citations
11.
Reisberg, ‌Barry, Rachelle S. Doody, Albrecht Stöffler, et al.. (2003). Memantine in Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine. 348(14). 1333–1341. 1510 indexed citations breakdown →
12.
Wimo, Anders, et al.. (2003). Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s Disease. PharmacoEconomics. 21(5). 327–340. 125 indexed citations
13.
Schmitt, Frederick A., Dona E. Cragar, J. Wesson Ashford, et al.. (2002). Measuring cognition in advanced Alzheimer’s disease for clinical trials. Journal of neural transmission. Supplementum. 135–148. 37 indexed citations
14.
Möbius, Hans Jörg & Albrecht Stöffler. (2002). New Approaches to Clinical Trials in Vascular Dementia: Memantine in Small Vessel Disease. Cerebrovascular Diseases. 13(Suppl. 2). 61–66. 22 indexed citations
15.
Winblad, Bengt, Hans Jörg Möbius, & Albrecht Stöffler. (2002). Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?. Journal of neural transmission. Supplementum. 217–225. 26 indexed citations
16.
Möbius, Hans Jörg & Albrecht Stöffler. (2002). Long-term treatment with memantine in advanced AD. European Neuropsychopharmacology. 12. 135–135. 1 indexed citations
17.
Orgogozo, Jean‐Marc, et al.. (2002). Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia. Stroke. 33(7). 1834–1839. 351 indexed citations
18.
Danysz, Wojciech, Chris G. Parsons, Hans Jörg Möbius, Albrecht Stöffler, & G. Quack. (2000). Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research. 2(2-3). 85–97. 207 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Jörg Möbius Breakdown of academic impact, for papers by R. H. Perry Breakdown of academic impact, for papers by Michelle Gee Breakdown of academic impact, for papers by G K Wilcock Breakdown of academic impact, for papers by Richard Harvey Breakdown of academic impact, for papers by F. Müller‐Spahn Breakdown of academic impact, for papers by Lutz Froelich Breakdown of academic impact, for papers by Peter Bentham Breakdown of academic impact, for papers by Lynn D. Kramer Breakdown of academic impact, for papers by Taro Kishi
Rankless by CCL
2026